A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ConditionAdvanced Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorImmuneOncia Therapeutics Inc.
About this trial
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
Eligibility criteria
Qualifiers
Signed ICF
Adult (19 years or older)
Diagnosis and prior therapies
Histologically or cytologically proven metastatic or locally advanced of hepatocellular carcinoma (excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors)
Disqualifiers
Treatment with nonpermitted drugs
Prior treatment with a CD47 or SIRPα targeting agent
Concurrent anticancer treatments
Major surgery or significant traumatic injury prior to Screening or planned major surgery during the study period
Trial design
Treatments tested in this trial
- IMC-002
Treatment groups
62 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov